Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

NCT ID: NCT01135056

Last Updated: 2018-04-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 360 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-07-31
• Study Completion Date: 2018-07-31

Brief Summary

The primary objective of this study is to assess the efficacy of SIRT as compared with Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS).

The Study null hypothesis is, there is no difference in overall survival between patients receiving SIRT and those receiving Sorafenib therapy.

Detailed Description

Hepatocellular carcinoma (HCC) is the 5th most common cancer worldwide but unfortunately between 70 - 80% of all HCC are in the Asia-Pacific because of the prevalence of chronic viral hepatitis in the region. The increase in the prevalence of chronic hepatitis C in the Western world however predicts that HCC will similarly be an important cause of death there in the next 20 years.

Only 15-20% of HCC are today potentially curable by surgery at the time of diagnosis. Another 10-15% of patients may benefit from potentially curative locally ablative therapy such as radio-frequency ablation. Prognosis in the majority of patients has been dismal as conventional systemic therapies have been largely inefficacious. The first successfully trialed systemic targeted therapy, sorafenib (2007) prolonged survival by a modest average of 3 months in patients with good underlying liver function.

While the liver is radio-sensitive, external beam radiation causes significant radio-toxicity. To overcome this, selective internal radiation therapy (SIRT) was developed to deliver a radiation source directly to liver cancer via the arterial route. Sir-sphere is radioactive yttrium on a 90 micro-meter diameter resin carrier and is an established therapy in colorectal metastasis. Sir-sphere has been reported to cause significantly tumour regression in HCC.

This study will evaluate the efficacy of SIRT using SIR-Spheres yttrium-90 microspheres compared to sorafenib in the treatment of patients with locally advanced primary HCC.

Conditions

Hepatocellular Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sorafenib, Multikinase Inhibitor, Tablet

Sorafenib tosylate:

Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation.

Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma.

Group Type: ACTIVE_COMPARATOR

Sorafenib tosylate

Intervention Type: DRUG

Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops

SIR-Spheres, Microspheres, Device

SIR-Spheres:

SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value.

SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver.

Group Type: ACTIVE_COMPARATOR

SIR-Spheres

Intervention Type: DEVICE

One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.

Interventions

SIR-Spheres

One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.

Intervention Type: DEVICE

Sorafenib tosylate

Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops

Intervention Type: DRUG

Other Intervention Names

Yttrium-90 Microspheres; Nexavar

Eligibility Criteria

Inclusion Criteria

• Disease must be locally advanced as defined by BCLC (B) intermediate stage or BCLC (C) advanced stage without extra-hepatic disease (only with branch portal vein thrombosis).
• Willing, able and mentally competent to provide written informed consent prior to any testing undertaken for this study protocol, including screening tests and evaluations that are not considered to be part of the subject's routine care.
• Aged 18 years/older (either gender).
• Unequivocal diagnosis of HCC.
• HCC not amenable to surgical resection or immediate liver transplantation, or cannot be optimally treated with local ablative techniques such as RFA, consistent with the practice of the clinical trial centre.
• Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with spiral CT scan or MRI.
• ECOG performance status 0-1.
• Child-Pugh A-B (up to 7 points)
• Adequate haematological, renal and hepatic function as follows:
• Leukocytes ≥ 2,500/μL
• Platelets ≥ 80,000/μL
• Haemoglobin > 9.5g/dL
• Total bilirubin < 2.0mg/dL
• INR ≤ 2.0
• ALP ≤ 5 x institutional ULN
• AST and ALT ≤ 5 x institutional ULN
• Albumin ≥ 2.5g/dL
• Creatinine ≤ 2.0mg/dL
• Life expectancy of at least 3 months without any active treatment.
• Suitable for protocol treatment as determined by clinical assessment undertaken by the Investigator.
• Female patients must be either postmenopausal or, if premenopausal, must have a negative pregnancy test and agree to use 2 forms of contraception if sexually active during their study participation.
• Male patients must be surgically sterile, or if sexually active and having a pre-menopausal female partner then must be using an acceptable form of contraception.

Exclusion Criteria

• Have had more than 2 administrations of hepatic artery directed therapy.
• Subjects who have had hepatic artery directed therapy done < 4 weeks prior to study entry.
• Have had systemic chemotherapy for HCC except for prior adjuvant or neoadjuvant therapy given more than 6 months from enrolment.
• have had prior treatment with Sorafenib or VEGF inhibitors.
• Prior hepatic radiation therapy for HCC or other malignancy.
• Currently receiving any other investigational agents for the treatment of their cancer.
• Has intractable clinical ascites (in spite of optimal diuretic treatment) or any other clinical signs of liver failure, on physical examination.
• Complete main portal vein thrombosis.
• Any metastatic disease (local-regional lymph nodes measuring less than 2 cm in greatest diameter or lung nodules measuring less than 1 cm are not contraindications as per Investigator discretion).
• Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 5 years.
• Presence of clinical signs of CNS metastases due to their poor prognosis and because progressive neurologic dysfunction would confound the evaluation of neurologic and other adverse events.
• Uncontrolled inter-current illness including, but not limited to, ongoing or active infection (except viral hepatitis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Any of the following contraindications to angiography and selective visceral catheterization:
• Bleeding diathesis, not correctable by the standard forms of therapy.
• Severe peripheral vascular disease that would preclude arterial catheterization.
• Portal hypertension with hepato-fugal flow as documented on baseline spiral CT scan.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to SIR-Spheres or Sorafenib.
• Inability or unwillingness to understand or sign a written informed consent document.
• Female subjects who are pregnant or currently breastfeeding.
• Female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as per Investigator discretion during the study. The rhythm method is not to be used as the sole method of contraception.
• Male subjects, unwillingness to practice effective contraception (per Investigator discretion) while taking part in this study, because the effect of the SIR-Spheres treatment on sperm or upon the development of an unborn child are unknown.
• Current enrolment in any other investigational therapeutic drug or device study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Centre, Singapore

OTHER

Sponsor Role: collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

Sponsor Role: collaborator

Singapore Clinical Research Institute

OTHER

Sponsor Role: collaborator

Sirtex Medical

INDUSTRY

Sponsor Role: collaborator

Singapore General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pierce KH Chow, MBBS, PhD

Role: STUDY_CHAIR

National Cancer Centre, Singapore

Locations

The Brunei Cancer Centre

Kampong Jerudong, Brunei, Brunei

Yangon GI & Liver Centre

Yangon, , Burma

Queen Mary Hospital

Hong Kong, Hong Kong, China

University of Udayana, Rumah Sakit Sanglah, Indonesia

Denpasar, Bali, Indonesia

Cipto Mangunkusumo Hospital ,University of Indonesia

Jakarta, , Indonesia

Penang Adventist Hospital

George Town, Pulau Pinang, Malaysia

Sarawak General Hospital

Kuching, Sarawak, Malaysia

University Malaya Medical Center

Kuala Lumpur, , Malaysia

National Cancer Center of Mongolia

Ulaanbaatar, , Mongolia

Auckland City Hospital

Grafton, Auckland, New Zealand

Makati Medical Center

Manila, Makati City, Philippines

The Medical City

Pasig, Manila, Philippines

St. Luke's Medical Center, Philippines

Quezon City, Manila, Philippines

Davao Doctors Hospital

Davao City, , Philippines

National University Hospital

Singapore, , Singapore

Singapore General Hospital

Singapore, , Singapore

National Cancer Center Singapore

Singapore, , Singapore

Khoo Teck Puat Hospital

Singapore, , Singapore

Severance Hospital, Yonsei University College of Medicine

Seoul, , South Korea

Korea University Anam Hospital

Seoul, , South Korea

Seoul St. Mary's Hospital

Seoul, , South Korea

Asan Medical Center

Seoul, , South Korea

Seoul National University Bundang Hospital

Seoul, , South Korea

National Taiwan University Hospital

Taipei City, Taipei, Taiwan

Taipei Veterans General Hospital

Taipei City, Taipei, Taiwan

Chang Gung Memorial Hospital

Taoyuan District, Taoyuan Hsien, Taiwan

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

China Medical University Hospital

Taichung, , Taiwan

Chulabhorn Hospital

Bangkok, , Thailand

Countries

Brunei; Burma; China; Indonesia; Malaysia; Mongolia; New Zealand; Philippines; Singapore; South Korea; Taiwan; Thailand

References

Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018 Jul 1;36(19):1913-1921. doi: 10.1200/JCO.2017.76.0892. Epub 2018 Mar 2.

Reference Type: DERIVED

PMID: 29498924 (View on PubMed)

Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer. 2016 Nov 7;16(1):856. doi: 10.1186/s12885-016-2868-y.

Reference Type: DERIVED

PMID: 27821083 (View on PubMed)

Related Links

http://www.scri.edu.sg/crn/asia-pacific-hepatocellular-carcinoma-ahcc-trials-group/about-ahcc/

AHCC Trials Group

Other Identifiers

AHCC06

Identifier Type: -

Identifier Source: org_study_id